| Platinum-Resistant Primary Peritoneal Carcinoma studied in …STUDIED_INderived31 of 31show fewer |
|---|
| → studied in | NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026062Phase 2 · completed Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped CURATED_BROADER · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616534Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113487Phase 2 · active not recruiting P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05465941Phase 2 · active not recruiting PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02650986Phase 1/Phase 2 · active not recruiting Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587311Phase 2 · active not recruiting Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05538091Phase 2 · recruiting Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04055649Phase 2 · recruiting ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730347Phase 2 · recruiting A Study of Lorigerlimab in Participants With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05271318Phase 1/Phase 2 · active not recruiting Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483048Phase 1 · recruiting MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04781088Phase 2 · active not recruiting Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05483933Phase 1 · completed Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04019288Phase 1/Phase 2 · terminated AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672095Phase 1/Phase 2 · withdrawn Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03508570Phase 1 · completed Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03206047Phase 1/Phase 2 · completed Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06867562Phase 3 · not yet recruiting Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03907527Phase 1 · active not recruiting Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691376Phase 1 · terminated Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04244552Phase 1 · terminated A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05295589Phase 2 · withdrawn Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy · condition mapped CURATED_BROADER · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04678102Phase 1 · unknown Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02898207Phase 1 · completed Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04753216Phase 2 · completed Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 31 trials mapped (16 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |